Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells

Oncology Reports

Volumn 15, Issue 1, 2006, Pages 79-83

  Nakamura, Takeshi ^a   Ozawa, Soji ^a   Kitagawa, Yuko ^a   Ueda, Masakazu ^a   Kubota, Tetsuro ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

A 431; Angiogenesis; Squamous cell carcinoma; SU6668; Xenograft model

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CHEMISTRY; DRUG SCREENING; ESOPHAGUS TUMOR; HUMAN; MOUSE; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); SQUAMOUS CELL CARCINOMA; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; CARCINOMA, SQUAMOUS CELL; ENDOTHELIUM, VASCULAR; ESOPHAGEAL NEOPLASMS; HUMANS; INDOLES; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33644873854     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.1.79     Document Type: Article

References (33)

1. Lerut T, Deleyn P, Coosemans W, et al: Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg 216: 583-590, 1992.
2. Akiyama H, Tsurumaru M, Udagawa H and Kajiyama Y: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 220: 364-373, 1994. (Pubitemid 24313229)
3. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y and Kitajima M: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 232: 225-232, 2000. (Pubitemid 30616724)
4. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
5. Takanami I, Imamura T, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T and Kodaira S: Immunohistochemical detection of basic fibroblast growth factor as a prognostic indicator in pulmonary adenocarcinoma. Jpn J Clin Oncol 26: 293-297, 1996. (Pubitemid 126470686)
6. Takebayashi Y, Miyadera K, Akiyama S, Hokita S, Yamada K, Akiba S, Yamada Y, Sumizawa T and Aikou T: Expression of thymidine phosphorylase in human gastric carcinoma. Jpn J Cancer Res 87: 288-295, 1996. (Pubitemid 26117060)
7. Maeda K, Kang SM, Ogawa M, Onoda N, Sawada T, Nakata B, Kato Y, Chung YS and Sowa M: Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer 74: 545-550, 1997. (Pubitemid 27486514)
8. Li Z, Shimada Y, Uchida S, Maeda M, Kawabe A, Mori A, Itami A, Kano M, Watanabe G and Imamura M: TGF-α as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol 17: 453-460, 2000.
9. Kuwahara K, Sasaki T, Kuwada Y, Murakami M, Yamasaki S and Chayama K: Expression of angiogenic factors in pancreatic ductal carcinoma. A correlative study with clinicopathologic parameters and patient survival. Pancreas 26: 344-349, 2003. (Pubitemid 36529959)
10. Kaio E, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K and Chayama K: Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 64: 61-73, 2003. (Pubitemid 35477956)
11. Shih CH, Ozawa S, Ando N, Ueda M and Kitajima M: Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 6: 1161-1168, 2000. (Pubitemid 30159380)
12. Wojtowicz-Praga SM, Dickson RB and Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 15: 61-75, 1997. (Pubitemid 27217752)
13. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP and McMahon G: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106, 1999. (Pubitemid 29062964)
14. Erlichman C, Adjei AA, Alberts SR, Sloan JA, Goldberg RM, Pitot HC, Rubin J, Atherton PJ, Klee GG and Humphrey R: Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol 12: 389-395, 2001. (Pubitemid 32288697)
15. Falardeau P, Champagne P, Poyet P, Hariton C and Dupont E: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28: 620-625, 2001. (Pubitemid 33134422)
16. Hoekman K: SU6668, a multitargeted angiogenesis inhibitor. Cancer J 7: S134-138, 2001.
17. Naglich JG, Jure-Kunkel M, Gupta E, Fargnoli J, Henderson AJ, Lewin AC, Talbott R, Baxter A, Bird J, Savopoulos R, Wills R, Kramer RA and Trail PA: Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 61: 8480-8485, 2001. (Pubitemid 33131128)
18. Sridhar SS and Shepherd FA: Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 42: S81-91, 2003. (Pubitemid 37378191)
19. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G and Cherrington JM: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60: 4152-4160, 2000. (Pubitemid 30636598)
20. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G and Ellis LM: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59: 5412-5416, 1999. (Pubitemid 29526446)
21. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM and Abott BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems (3rd edition). Cancer Chemother Rep 3: 51-61, 1972.
22. Kubota T, Nakada M, Tsuyuki K, Ishibashi K and Abe O: Cell kinetics and chemosensitivity of human carcinoma serially transplanted into nude mice. Jpn J Cancer Res 77: 502-507, 1986. (Pubitemid 16088155)
23. Sato Y, Mukai K, Watanabe S, Goto M and Shimosato Y: The AmeX method; a simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol 125: 431-435, 1986. (Pubitemid 17208827)
24. Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB and Cherrington JM: SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 16: 681-690, 2002. (Pubitemid 34465432)
25. Ning S, Laird D, Cherrington JM and Knox SJ: The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157: 45-51, 2002. (Pubitemid 34073387)
26. Lu B, Geng L, Musiek A, Tan J, Cao C, Donnelly E, McMahon G, Choy H and Hallahan DE: Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. Int J Radiat Oncol Biol Phys 58: 844-850, 2004. (Pubitemid 38221141)
27. Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI and Giavazzi R: The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res 9: 3476-3485, 2003. (Pubitemid 37082747)
28. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H and Song CW: Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 62: 1702-1706, 2002. (Pubitemid 34408492)
29. Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF and Gorelik E: Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res 62: 5727-5735, 2002. (Pubitemid 35204728)
30. Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej CA and Abbruzzese JL: A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 22: 459-466, 2004. (Pubitemid 39619822)
31. Marzola P, Degrassi A, Calderan L, Farace P, Crescimanno C, Nicolato E, Giusti A, Pesenti E, Terron A, Sbarbati A, Abrams T, Murray L and Osculati F: In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 10: 739-750, 2004. (Pubitemid 38174012)
32. Machida S, Saga Y, Takei Y, Mizuno I, Takayama T, Kohno T, Konno R, Ohwada M and Suzuki M: Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). Int J Cancer 114: 224-229, 2005. (Pubitemid 40194290)
33. Tokuyama J, Kubota T, Saikawa Y, Yoshida M, Furukawa T, Otani Y, Kumai K and Kitajima M: Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis. Anticancer Res 25: 17-22, 2005. (Pubitemid 40470086)